Proton MRS and quantitative MRI assessment of the short term neurological response to antiretroviral therapy in AIDS

Journal of Neurology Neurosurgery and Psychiatry

Volumn 63, Issue 4, 1997, Pages 477-482

  Wilkinson, Iain D ^a,c   Lunn, Sarah ^b   Miszkiel, Katherine A ^a   Miller, Robert F ^b   Paley, Martyn N J ^b   Williams, Ian ^b   Chinn, Roger J S ^a   Hall Craggs, Margaret A ^a   Newman, Stanton P ^b   Kendall, Brian E ^a   Harrison, Michael J G ^b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

Human immunodeficiency virus; Magnetic resonance spectroscopy; Zidovudine

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLINE; CREATINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL TRIAL; DEMENTIA; DISEASE COURSE; GRAY MATTER; HUMAN; MALE; METABOLITE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; PARIETAL LOBE; PATIENT MONITORING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; WHITE MATTER;

EID: 0030822186     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.63.4.477     Document Type: Article

References (30)

1. Harrison MJG, McArthur JC. AIDS and neurology. London: Churchill Livingstone, 1995.
2. Olsen WL, Longo FM, Mills CM, Norman D. White matter disease in AIDS: findings at MR imaging. Radiology 1988; 169:445-8.
3. Dooneief G, Bello J, Todak G, et al. A prospective controlled study of magnetic resonance imaging of the brain in gay men and parenteral drug users with human immunodeficiency virus infection. Arch Neurol 1992;49: 38-42.
4. Post MJD, Berger JR, Quencer RM. Asymptomatic and neurologically symptomatic HIV-seropositive individuals: prospective evaluation with cranial MR imaging. Radiology 1991;178:131-9.
5. Tozzi V, Narciso P, Galgani S, Sette P, Balestra P, Gerace C, et al. Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex. AIDS 1993;7: 683-92.
6. Wilkinson ID, Chinn RJS, Paley MNJ, Hall-Craggs MA, Miller RF, Kendall BE, Harrison MJG. Sub-cortical white-grey matter contrast on MRI as a quantitative marker for diffuse HIV-related parenchymal abnormality. Clin Radiol 1996;51:475-9.
7. Paley M, Chong W, Wilkinson ID, Shepherd JK, Clews A, Sweeney BJ, et al. Cerebrospinal fluid - Intracranial volume ratio measurements in patients with HIV infection: CLASS image analysis technique. Radiology 1994;190:879-86.
8. Menon DK, Baudouin CJ, Tomlinson D, Hoyle C. Proton MR spectroscopy and imaging of the brain in AIDS: evidence of neuronal loss in regions that appear normal with imaging. J Comput Assist Tomogr 1990;14: 882-5.
9. Chong WK, Sweeney B, Wilkinson ID, Paley M, Hall-Craggs MA, Kendall BE, et al. Proton spectroscopy of the brain in HIV infection: correlation with clinical, immunologic and MR imaging findings. Radiology 1993;188:119-24.
10. Meyerhoff DJ, MacKay S, Bachman L, Poole N, Dillon WP, Weiner MW, Fein G. Reduced brain N-acetylaspartate suggests neuronal loss in cognitively impaired human immunodeficiency virus-seropositive individuals: in-vivo H magnetic resonance spectroscopic imaging. Neurology 1993;43: 509-15.
11. Paley M, Wilkinson ID, Hall-Craggs MA, Chong WK, Chinn RJS, Harrison MJG. Short echo time proton spectroscopy of the brain in HIV infection / AIDS. Magn Reson Imaging 1995;13:871-5.
12. Jarvick JG, Lenkinski RE, Grossman RI, Frank I, Ramer KN. Proton MR spectroscopy in HIV-infected patients: characterization of abnormalities with imaging and clinical correlation. Radiology 1993;186:739-44.
13. Everall IP, Luthert PJ, Lantos PL. Neuronal loss in the frontal cortex in HIV infection. Lancet 1991;337: 1119-21.
14. Wilkinson ID, Hall-Craggs MA, Chong WK, Paley M, Noble P, Harrison MJG, Weller IVD. Increase in NA/Cr metabolite ratio following anti-retroviral drug therapy in AIDS: a case study. In: Book of abstracts: 12th Annual Meeting of the Society of Magnetic Resonance in Medicine. Vol 3. Berkeley CA: SMRM, 1993:1560.
15. Vion-Dury J, Nicoli F, Salvan A, Confort-Gouny S, Dhiver C, Cozzone PJ. Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonsnce spectroscopy. Lancet 1995;345:60-1.
16. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HFV-1) infection. Neurology 1991;41:778-85.
17. CDC. Revised classification system for HIV infection and expanded case definitions for AIDS among adolescents and adults. MMWR 1992;41:1-19.
18. Fox JD, Brink NS, Zuckerman MA, et al. Detection of herpesvirus DNA by nested polymerase chain reaction in cerebrospinal fluid of human immunodeficiency virus-infected persons with neurologic disease: a prospective evaluation. J Infect Dis 1995;172:1087-90.
19. Wilkinson ID, Chinn RJS, Paley M, Sweeney B, Maloney MA, Chong WK, et al. Serial proton spectroscopy of brain parenchyma in HIV infection. In: Book of abstracts: Second Meeting of the Society of Magnetic Resonance. Vol 2. Berkeley CA: SMR, 1994:582.
20. Wilkinson ID, Paley M, Chong WK, Sweeney B, Shepherd JK, Kendall BE, et al. Proton spectroscopy in HIV infection: relaxation times of cerebral metabolites. Magn Reson Imaging 1994;12:951-7.
21. Yarchoan R, Berg G, Brouwers P, Fischl MA, Spitzer AR, Wichman A, et al. Response of human-immunodeficiency-virus-associated neurological disease to 3′ -azido- 3′ -deoxythimidine. Lancet 1987;i:132-5.
22. Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, Druckner JL, The AZT collaborative working group. Neuropsychological outcome of Zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1988;319:1573-8.
23. Loveday C, Kaye S, Tenant-Flowers M, Semple M, Ayliffe U, Weller IVD, Tedder RS. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet 1995;345:820-4.
24. Yeni P, on behalf of the European / Australian Delta trial: based on data up to 31 May 1995. 5th European congress on clinical aspects and treatment of HIV infection. Copenhagen: September, 1995.
25. Dal Pan GJ, McArthur JH, Aylward E, Selnes OA, Nance-Sproson TA, Kumar AJ, Mellits ED, McArthur JA. Patterns of cerebral atrophy in HIV-1 - infected individuals: results of a quantitative MRI analysis. Neurology 1992;42: 2125-30.
26. Miller RF, Lucas SB, Hall-Craggs M, Brink NS, Scaravilli F, Chinn RJS, et al. A comparison of MR imaging and CSF analysis with neuropathological findings in the diagnosis of HIV and CMV associated CNS disease in AIDS. Journal of Neurovirology 1996;2:44.
27. Wilkinson ID, Miller RF, Paley MNJ, Miszkiel KA, Kendall BE, Hall-Craggs MA, Harrison MJG. Cerebral proton magnetic resonance spectroscopy in cytomegalovirus encephalitis and HIV leucoencephalopathy/encephalitis. AIDS 1996;10:1443-4.
28. Meyerhoff DJ, MacKay S, Poole N, Dillon WP, Weiner MW, Fein G. N-acerylaspartate reductions measured by 1H MRSI in cognitively impaired HIV-seropositive individuals. Magn Reson Imaging 1994;12:653-9.
29. Barker PB, Lee RR, McArthur J. AIDS dementia complex: evaluation with proton MR spectroscopic imaging. Radiology 1995;195:58-64.
30. Hall-Craggs MA, Williams I, Wilkinson ID, Paley MNJ, Chinn RJS, Weller IVD, et al. Proton spectroscopy in a cross-section of HIV positive asymptomatic patients receiving immediate compared with deferred zidovudine (concorde study). J Neuro-AIDS 1996:1:103-13.